Clinical trials: Breast Cancer Nos Metastatic Recurrent
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved…
- Trial name
- NCT02030678
- Testing
- irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Cancer
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00031876
- Testing
- capecitabine, paclitaxel
- Where
- 2 sites in Switzerland
- Volunteers
- 34 people
- Sponsor
- Swiss Cancer Institute
HER2-positive Breast Cancer
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
This is a phase II trial exploring the maintenance therapy with trastuzumab combined with pyrotinib or dalpiciclib and endocrine therapy in HER2-positive advanced breast cancer based on different hormone receptor (HR) statuses…
- Trial name
- NCT07179939
- Testing
- Trastuzumab rezetecan, Pyrotinib, Dalpiciclib
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Fudan University
Triple-Negative Breast Cancer (TNBC)
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
This is a single-arm, prospective, Phase II clinical trial designed to assess the efficacy and safety of QL1706 in combination with olaparib in patients with recurrent or metastatic triple-negative breast cancer (TNBC) harboring…
- Trial name
- NCT07005583
- Testing
- QL1706 Plus Olaparib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Breast Cancer
Early Interim 18F-FDG-PET and 18F-FLT-PET for Predicting Treatment Response and Survival in Metastatic Breast Cancer
We aim to investigate the value of 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for early prediction of treatment response and survival…
- Trial name
- NCT04411966
- Testing
- 18F-fluorothymidine
- Volunteers
- 32 people
- Sponsor
- Chang Gung Memorial Hospital
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer.
- Trial name
- TRIBECA (NCT02064829)
- Testing
- Nab-paclitaxel, IG-001
- Where
- 20 sites in United States, Georgia and 5 more
- Volunteers
- 111 people
- Sponsor
- Sorrento Therapeutics, Inc.
Breast Cancer
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
This study is an open-label, multicenter, randomized controlled study. It is planned to include 258 patients with HR +/HER2- advanced breast cancer with visceral metastases.
- Trial name
- NCT07467330
- Testing
- dalpiciclib + capecitabine + endocrine therapy, dalpiciclib + endocrine therapy
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Fujian Cancer Hospital
Estrogen Receptor Positive, HER2/Neu Negative
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
This partially randomized phase I trial is studying the side effects and the best dose of RO4929097 when given together with exemestane and to see how well it works compared to exemestane alone in treating premenopausal and…
- Conditions
- Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Recurrent Breast Carcinoma
- Trial name
- NCT01149356
- Testing
- Exemestane, Gamma-Secretase Inhibitor RO4929097, Goserelin Acetate
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Everolimus has been approved to be effective when used with exemestane after progression on non-steroidal aromatase inhibitors in postmenopausal women based on the BOLERO-2 clinical trial.
- Trial name
- MIRACLE (NCT02313051)
- Testing
- Everolimus, Goserelin, Letrozole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Neoplasms, Breast Neoplasms
Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)
The main purpose of this study is to determine if AZD8931 can improve the efficacy of standard chemotherapy for the treatment of advanced breast cancer.
- Conditions
- Neoplasms, Breast Neoplasms, Breast Cancer
- Trial name
- THYME (NCT00900627)
- Testing
- AZD8931, Paclitaxel
- Where
- 38 sites in Belgium, Brazil and 12 more
- Volunteers
- 330 people
- Sponsor
- AstraZeneca
HER2-positive Breast Cancer
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for…
- Trial name
- DEMETHER (NCT06172127)
- Testing
- Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 165 people
- Sponsor
- MedSIR
Estrogen Receptor Negative, Estrogen Receptor Positive
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
The main purpose of this study is to determine the anti-tumor activity of MEDI4736 in combination with tremelimumab in patients with metastatic HER2-negative breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Recurrent Breast Carcinoma
- Trial name
- NCT02536794
- Testing
- Anti-B7H1 Monoclonal Antibody MEDI4736, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Cancer
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant.
- Trial name
- NCT00110045
- Testing
- caspofungin acetate
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 171 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have a dose escalation to identify the maximum tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and…
- Trial name
- NCT02684032
- Testing
- Gedatolisib, Palbociclib, Letrozole
- Where
- 41 sites in United States
- Volunteers
- 141 people
- Sponsor
- Celcuity Inc
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Breast Cancer
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258375
- Testing
- custirsen sodium, docetaxel
- Where
- 5 sites in Canada
- Volunteers
- 15 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer, Lung Cancer
Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer
RATIONALE: Zoledronate, vitamin D and calcium may prevent or delay bone pain and other symptoms caused by bone metastases. It is not yet known whether giving zoledronate together with vitamin D and calcium is more effective with…
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00365105
- Testing
- Calcium, Vitamin D, zoledronic acid
- Where
- 147 sites in United States
- Volunteers
- 261 people
- Sponsor
- Radiation Therapy Oncology Group
Breast Cancer
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously…
- Trial name
- NCT00437294
- Testing
- enzastaurin, capecitabine
- Where
- 20 sites in Argentina, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
CP-724,714 in Treating Patients With Metastatic Breast Cancer
RATIONALE: CP-724,714 may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase I trial to study the effectiveness of CP-724,714 in treating patients who have metastatic…
- Trial name
- NCT00055926
- Testing
- CP-724,714
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center